Abstract
Purpose
To report a case of a full-thickness macular hole after a single intravitreal injection of ranibizumab in a patient with choroidal neovascularization associated with age-related macular degeneration.
Case summary
A 63-year-old woman presented to our department with gradually decreasing vision in her right eye. Best corrected visual acuity (BCVA) was measured as 0.7 in the right eye and 1.0 in the left eye. Examination of the macula showed a choroidal neovascularization associated with subretinal hemorrhage in the right eye. Optical coherence tomog-raphy (OCT) confirmed incomplete posterior vitreous detachment, subretinal hemorrhage and serous elevation. The pa-tient subsequently received an intravitreal ranibizumab injection. After 1 month, the best corrected visual acuity in the right eye was decreased to 0.4, and fundus examination revealed posterior vitreous detachment and a macular hole. The pa-tient underwent pars plana vitrectomy with internal limiting membrane peeling and fluid-air exchange, SF6 gas injection, phacoemulsification and posterior chamber intraocular lens implantation. Three months later, the macular hole had closed completely and best visual acuity was 1.0.
References
1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verte-porfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1432–44.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1419–31.
3. Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neo- vascularization in pathologic myopia with intravitreal bevacizumab. Retina. 2006; 26:960–3.
4. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safe-ty worldwide. Br J Ophthalmol. 2006; 90:1344–9.
5. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients af-ter intravitreal injection of bevacizumab. Acta Ophthalmol. 2008; 86:372–6.
6. Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol. 1981; 65:417–22.
7. Lee GK, Lai TY, Chan WM, Lam DS. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-re-lated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1225–7.
8. Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol. 2006; 141:752–4.
9. Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epi-thelial tear following intravitreal bevacizumab (Avastin) in-jection for occult choroidal neovascularisation secondary to age re-lated macular degeneration. Br J Ophthalmol. 2006; 90:1207–8.
10. Shah CP, Hsu J, Garg SJ, et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol. 2006; 142:1070–2.
11. Jo YJ, Kim KN, Lee JE, Kim JY. Macular hole following intra-vitreal ranibizumab injections for choroidal neovascularization. J Korean Ophthalmol Soc. 2010; 51:774–8.
12. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011; 56:95–113.
13. Chan Ck, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subforveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol. 2007; 17:674–6.
14. Konstantinidis L, Ambresin A, Zografos L, Mantel I. Retinal pig-ment epithelium tears after intravitreal injection of ranibizumab for predominantly classic neovascular membranes secondary to age- related macular degeneration. Acta Ophthalmol. 2010; 88:736–41.
15. Chung EJ, Koh HJ. Retinal detachment with macular hole follow-ing combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol. 2007; 21:185–7.
16. Moisseiev E, Goldstein M, Loewenstein A, Moisseiev J. Macular hole following intravitreal bevacizumab injection in choroidal neo-vascularization caused by age-related macular degeneration. Case Report Ophthalmol. 2010; 18:36–41.